knowledge -WSS

knowledge

author：hotspot 2025-09-03 09:19:20 - browse：138

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Military medical care influenced by rank and race, new study finds

knowledge

entertainment

WSS

Ukrainian soldiers say they owe lives to US

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

Medical experts exlpore how to eliminate bias in clinical algorithms

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

HIV vaccine remains elusive. Immunologists keep trying new ideas

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Novavax promises a turnaround & Lilly roils the obesity market

ADA: All diabetes patients should be screened for liver condition

Wildfire smoke exposes gaps in outdoor worker protections

ADA: All diabetes patients should be screened for liver condition

The high cost of giving birth even with insurance

Ukrainian soldiers say they owe lives to US

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Wikipedia

Supreme Court rules employers must be more accommodating of religious observance

Belarusian journalist sentenced to 4 years in prison as crackdown continues

Helping hospitals and community health centers plan for resilience

Case highlights the risks of experimental stem cell therapy

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Readout LOUD podcast: Live from STAT Breakthrough Summit West

knowledge

entertainment

focus

knowledge